On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.

Impax was founded in 1995 as the privately held Impax Pharmaceuticals, Inc. focused on leveraging its scientific expertise in drug delivery technologies to develop niche and controlled release generic products. Since 1995, our company has evolved through organic growth and a series of acquisitions, to become a competitive specialty pharmaceutical company with a growing portfolio of generic and innovative specialty pharmaceutical products.

Some key highlights of our growth and evolution:

MARCH 1999 – Impax receives first new Abbreviated New Drug Application (ANDA) approval for minocycline HCI capsules.

DECEMBER 1999 – Publicly traded Global Pharmaceutical Corporation and Impax Pharmaceuticals, Inc. complete a reverse merger, forming Impax Laboratories, Inc. The merger combined Impax Pharmaceuticals drug development expertise with Global Pharmaceutical’s sales, marketing and distribution capabilities.

JULY 2006 – Impax launches Impax Pharmaceuticals, a division focused on branded central nervous system products. The branded division deployed its specialty sales force of 66 representatives through a contract sales arrangement with a third party to promote an anti-convulsant drug, a product of Shire plc.

FEBRUARY 2012 – Impax licenses the exclusive U.S. commercial rights to ZOMIG® (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations from AstraZeneca plc, and begins selling ZOMIG® products under our label.

JANUARY 2015 – Impax receives approval for RYTARY® (carbidopa and levodopa), an extended-release oral capsule formulation of carbidopa-levodopa. This significant milestone marks the Company’s first branded drug internally developed and approved for commercialization.

MARCH 2015 – Impax acquires Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC), and Lineage Therapeutics Inc. As a result, the Company realigns its two divisions as Impax Generics and Impax Specialty Pharma.

AUGUST 2016 – Impax expands its generics portfolio by acquiring a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms from Teva Pharmaceutical Industries Ltd. and affiliates of Allergan plc.

OCTOBER 2017 – Impax and Amneal announce a definitive agreement to combine, creating a diversified pharmaceutical company with a robust U.S. generics business and growing branded franchise.

MAY 2018 – Impax and Amneal combine under Amneal Pharmaceuticals, Inc. (NYSE:AMRX).